Reduces elevated serum total and LDL-C. ANDA 215223, held by Zydus Pharms. Colestipol Hydrochloride.
As of Nov 16, 2026, ANDA 215223 (Colestipol Hydrochloride), held by Zydus Pharms, was first approved by FDA on Mar 10, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 10, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colestipol Hydrochloride1GM · tablet;oral | Colestipol Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters